Abstract Library

#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma

Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Martin C, Mitrache M, Nitipir C, Terzea D, Stroescu C,

Keywords: pulmonary neuroendocrine tumors, pituitary macroadenoma,

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,

#1687 Pancreatic well-differentiated neuroendocrine tumor with grade 3 does not respond to platinum-based chemotherapy: a multicenter study of neuroendocrine carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S,

Keywords: NET-G3, NEC, KRAS, Rb,

#1595 Pathological Features of High Proliferative Activity Neuroendocrine Tumor

Introduction: High Proliferative Activity Neuroendocrine Tumor (NET G3) is difficult to be distinguished from neuroendocrine carcinoma. However, there are differences in clinical treatment and prognosis between the two. So it is crucial to make an accurate pathological diagnosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Geng H, Shi S,

Keywords: high proliferative activity, neuroendocrine tumor, pathological feature,

#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas

Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F,

Keywords: everolimus, poorly differentiated neuroendocrine carcinoma, preclinical study,